Key result
Urgent heart transplantation and modified chemotherapy resulted in 5.5 years of survival without oncological relapse or heart failure symptoms in a patient with primary cardiac lymphoma.
Why the study?
Cancer patients usually have a slim chance of receiving heart transplantation, though it is not an absolute contraindication, and data on managing primary cardiac lymphoma with urgent transplantation remain limited.
Case Report (n=1)
Urgent heart transplantation combined with a modified chemotherapy regimen can be a viable, long-term successful strategy for selected patients with primary cardiac lymphoma presenting with refractory ventricular tachycardia storm.
Background Primary cardiac lymphoma (PCL) involves the heart almost exclusively although it can extend to surrounding structures including the pericardium. Most PCLs in adults are of B-cell origin and their signs and symptoms are generally non-specific and depend on their location and size. In general, cancer patients usually have a slim chance of receiving heart transplantation (OHT), although it’s not an absolute contraindication depending on the decision of the multidisciplinary team and the experience of each institution. Case Summary A 48-year-old man, with an ultimate diagnosis of primary cardiac follicular B-cell lymphoma presented to our hospital mimicking hypertrophic cardiomyopathy. He initially presented with worsening heart failure and ventricular tachycardia storm (VT-S) that required urgent cardiac OHT. The final pathological analysis of the explanted heart revealed the presence of a PCL without extra-cardiac extension. In addition to initial immunosuppression with mycophenolate mophethyl, corticosteroids, and tacrolimus, he was switched to Everolimus and dose reduction of Tacrolimus. Rituximab + Bendamustine was initiated to reduce the risk of cardiotoxicity and myelotoxicity associated to R-CHOP. The follow-up body PET-CT, trans-thoracic echocardiogram, cardiac magnetic resonance imagings and biopsies were normal. During a regular follow-up heart biopsy procedure to ascertain rejection, the patient developed torrential tricuspid regurgitation and required surgical valve replacement. Discussion After 5.5 years of follow-up, the patient remains asymptomatic, with normal graft function, in NYHA FC I, and without oncological relapses despite receiving a modified chemotherapy regimen. Selected patients with a PCL can be managed with OHT and a modified chemotherapy regimen. They could also be followed up using a non-invasive approach to monitor rejection.
No takes yet. Share an insight, caveat, or question.
Lugo-Peña et al. (2025) conducted a case report in Primary cardiac lymphoma (n=1). Orthotopic heart transplantation and modified chemotherapy was evaluated on Clinical status and oncological relapse. Urgent heart transplantation and modified chemotherapy resulted in 5.5 years of survival without oncological relapse or heart failure symptoms in a patient with primary cardiac lymphoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: